Gene Modified T Cell Therapies for Hematological Malignancies

Hematol Oncol Clin North Am. 2017 Oct;31(5):913-926. doi: 10.1016/j.hoc.2017.06.005.

Abstract

This article focuses on clinical applications of T cells transduced to express recombinant T cell receptor and chimeric antigen receptor constructs directed toward hematological malignancies, and considers newer strategies incorporating gene-editing technologies to address GvHD and host-mediated rejection. Recent data from clinical trials are reviewed, and an overview is provided of current and emerging manufacturing processes; consideration is also given to new developments in the pipeline.

Keywords: Adoptive immunotherapy; Chimeric antigen receptor; Gene editing; Gene therapy; Lentiviral vectors; Leukemia; Lymphoma; T cell receptor.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antigens, Neoplasm / genetics
  • Antigens, Neoplasm / immunology
  • Biotechnology
  • Cell- and Tissue-Based Therapy* / methods
  • Gene Editing
  • Genetic Engineering
  • Genetic Therapy* / methods
  • Genetic Vectors / genetics
  • Hematologic Neoplasms / genetics*
  • Hematologic Neoplasms / immunology
  • Hematologic Neoplasms / therapy*
  • Humans
  • Immunotherapy, Adoptive
  • Receptors, Antigen, T-Cell / genetics
  • Recombinant Fusion Proteins / genetics
  • T-Lymphocytes / immunology
  • T-Lymphocytes / metabolism*

Substances

  • Antigens, Neoplasm
  • Receptors, Antigen, T-Cell
  • Recombinant Fusion Proteins